# Samsung C\&T 3Q 2022 Earnings Release 

(Contents)

1. Samsung C\&T Results
2. Performance by Business Group
3. ESG, Investment, etc.

Appendix. Financial Statement Key Highlights

The figures in this document are consolidated earnings estimates based on K-IFRS.

Please be advised that this document is provided solely for the purpose of investor convenience. It was prepared before the completion of the external auditor's review, and therefore is subject to change during this process.

## 3Q 2022 Earnings Release Summary

$\square \operatorname{In}$ Q3, C\&T posted 11.3 tn (+3 tn YoY) in sales, 796.8 bn (+ 655.8 bn YoY ) in operating profit on the continued earnings momentum backed by strengthened competitiveness and diversified business portfolio, even amid the rapid shifts in the business environment caused by the global economic recession, etc.In Q3, cumulative orders totaled 13.6 tn driven by strong high-tech orders. C\&T adjusts its annual order guidance upward from 11.7 tn to $16.7 \mathrm{tn}(+42.7 \%)$ for having surpassed the annual target in the quarter.
[ Key Financial Indicators ]

|  | 2020 | 2021 | $3 Q 22$ |
| :---: | :---: | :---: | :---: |
| EBITDA $^{1)}$ | 1.37 tn | 1.71 tn | $2.36 \mathrm{tn}(7.3 \%)$ |
| Total Debt | 3.15 tn | 2.97 tn | 5.84 tn |
| Debt/Equity (\%) | $65 \%$ | $66 \%$ | $90 \%$ |

1) EBITDA (Cumulative) : Operating profit + depreciation and amortization cost
2) EBITDA margin : EBITDA / Sales
1. Samsung C\&T Results (K-IFRS Consolidated)

|  | 3Q22 | 2Q22 | QoQ Change | 3Q21 | YoY Change | 2022 Cum. (Q1~Q3) |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Sales | 11,256 | 10,819 | +437 | 8,303 | +2,953 | 32,514 |
|  | 4,189 | 3,359 | +830 | 2,407 | +1,782 | 10,567 |
| T\&1 | 4,796 | 5,415 | (619) | 4,363 | +433 | 15,992 |
| Fashion | 471 | 515 | (44) | 375 | +96 | 1,459 |
| Leisure | 227 | 220 | +7 | 134 | +93 | 534 |
| $F \& B *$ | 703 | 655 | +48 | 573 | +130 | 1,926 |
| Biologics** | 870 | 655 | +215 | 451 | +419 | 2,036 |
| Gross Profit | 1,744 | 1,391 | +353 | 815 | +929 | 4,394 |
| SG\&A | 947 | 835 | +112 | 674 | +273 | 2,500 |
| Operating Profit | 797 | 556 | +241 | 141 | +656 | 1,894 |
| E \& C | 324 | 155 | +169 | (130) | +454 | 634 |
| T \& I | 59 | 129 | (70) | 82 | (23) | 378 |
| Fashion | 29 | 62 | (33) | 17 | +12 | 132 |
| Leisure | 48 | 22 | +26 | 0 | +48 | 46 |
| F \& B* | 24 | 34 | (10) | 16 | +8 | 72 |
| Biologics** | 313 | 154 | +159 | 156 | +157 | 632 |
| Non-Operating Profit | 175 | 295 | (120) | 357 | (182) | 741 |
| Financial Profit | (115) | (37) | (78) | 16 | (131) | (141) |
| Equity Method Investment | 17 | 50 | (33) | 26 | (9) | 122 |
| Pre-Tax Profit | 874 | 864 | +10 | 540 | +334 | 2,616 |
| Net Profit | 597 | 633 | (36) | 375 | +222 | 1,879 |
| L Controlling | 495 | 515 | (20) | 294 | +201 | 1,571 |

* Welstory: 100\% Subsidiary, ** Biologics: $43.06 \%$ Subsidiary


## 2. Performance by Business Group: Engineering \& Construction



[^0]

- Earnings improved thanks to progress in high-tech constructions, revenue from new construction projects overseas, improved P\&L of completed projects at home and abroad, etc.

V New Orders
(KRWbillion)

|  | 3Q22 | 3Q22 Backlog |
| :---: | ---: | ---: |
| Total | 4,943 | 28,503 |
| Building | 4,801 | 15,888 |
| Civil | 57 | 3,204 |
| Plant | 85 | 9,411 |
| Domestic | 3,552 | 12,076 |
| Overseas | 1,391 | 16,427 |

※ Major Projects: Pyeongtaek FAB 42.3 tn, U.S. Taylor FAB 1.1 tn, Hwaseong HPC Center 0.3 tn, Yangpyeong 130.2 tn, etc.
※ Total \& Domestic include landscape orders of Resort
(New orders 30.5 bn, Backlog 154.1 bn)

## 2. Performance by Business Group: Trading \& Investment, Fashion

## Trading \& Investment

|  | 3Q22 | 2Q22 |  | 3Q21 |  | $\begin{aligned} & 3 Q 22 \\ & \text { Cum. } \end{aligned}$ |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  |  |  | Change |  | Change |  |
| Sales | 4,796 | 5,415 | (619) | 4,363 | +433 | 15,992 |
| Chemicals | 1,801 | 1,869 | (68) | 1,351 | +450 | 6,070 |
| Steel | 1,558 | 1,667 | (109) | 1,319 | +239 | 4,868 |
| Energy | 91 | 95 | (4) | 120 | (29) | 302 |
| Materials | 1,346 | 1,784 | (438) | 1,573 | (227) | 4,752 |
| Gross Profit | 297 | 315 | (18) | 261 | +36 | 954 |
| Operating Profit | 59 | 129 | (70) | 82 | (23) | 378 |

※Contributionto OP (3Q22 Cumulative): Trading (66\%), Operationsites (31\%), Business Development(3\%)
※Operationsites:Otelinoxstainlesspredisionmill,etc./ BusinessDevelopment:U.S. solarpowerdevelopment, etc.

| Fashion |  |  |  |  |  | (KRWWbillion) |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | 3Q22 | 2Q22 |  | 3Q21 |  | $\begin{aligned} & 3 Q 22 \\ & \text { Cum. } \end{aligned}$ |
|  |  |  | Change |  | Change |  |
| Sales | 471 | 514 | (43) | 375 | +96 | 1,459 |
| Operating Profit | 29 | 62 | (33) | 16 | +13 | 132 |

Trading \& Investment
 volume and unit prices have fallen with a decline in global trading volume, sluggish demand in the upstream industry, etc.

Fashion


- Earnings declined QoQ due to offpeak season. Yet, YoY earnings increased thanks to the continued growth of imported brands, online sales, and improved fast fashion business

2. Analysis by Business Group : Leisure, F\&B, Bio

Leisure


| F\&B |  |  |
| :--- | ---: | ---: | ---: | ---: | ---: | ---: | ---: |

* Welstory: 100\% Subsidiary


## Biologics

|  | 3Q22 | 2Q22 |  | 3Q21 |  | 3Q22 |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  |  |  | Change |  | Change |  |
| Sales | 870 | 655 | +215 | 451 | +419 | 2,036 |
| Operating Profit | 313 | 154 | +159 | 156 | +157 | 632 |



- Earnings continue to improve driven by growing park visitors and seasonality
- F\&B's earnings improved YoY with higher revenue driven by new cafeteria orders from non-group affiliates and the growth of the food distribution business
* Biologics: 43.06\% Subsidiary


## 3. ESG, Investment, etc.

## Investment/New Business Development

- C\&T's eco-friendly businesses have begun to take concrete shapes - Hydrogen: Continue to build partnerships for hydrogen production and utilization. Secure technological prowess by seeking a pilot project in UAE and cooperation with water electrolysis companies.
- Solar Power: Expand the pipeline of the U.S. solar power development business and advance into the Australian market. Seek EPC business opportunities in Australia and Southeast Asia drawing on its PV+ESS capability.
- SMR: Strengthen capability by seeking to participate in the construction of first SMR in the U.S. and prepare for global projects in East Europe, etc
- As for smart city business, C\&T will cooperate with modular companies and smart solution providers and strengthen its capability and seek business opportunities through pilot projects
- Participate in modular-based smart city projects in Saudi Arabia (e.g. NEOM), Southeast Asia, etc., and seek more opportunities as a renewables-based integrated service provider to smart city
- In Oct. 2022, Biologics completed the construction of Plant 4 the world's largest single bio plant (240,000 liters) and has started partial operations (global no. 1 company with the largest CMO capacity)
- Full utilization by 2023 to reach a total capacity of around 600,000 liters - Signed land purchase deal to construct its second Bio campus in July 2022


## ESG

- E\&C and Fashion received the highest grade in the 2022 Win-Win Growth Index (WWGI)
- Fashion Group is the first company in the industry to receive the highest WWGI grade and E\&C received the highest grade for three consecutive years from 2020 to 2022.
* Win-Win Growth Index: An indicator that evaluates corporate compliance with the Fair Trade Commission's Fair Trade Agreement (50\%) and the level of shared growth with SMEs through the Korea Commission for Corporate Partnership's survey (50\%)
- In its 2022 Sustainability Report, C\&T published its 2021 progress and 2023 targets aligned with its mid-to-long-term ESG strategy - Enhanced communication with stakeholders by including a climaterelated TCFD report in the Sustainability Report
- C\&T's roadmap to achieve Net Zero is in the course of development

|  | 3Q22 | 2Q22 |  | End of 2021 | Change |
| :---: | :---: | :---: | :---: | :---: | :---: |
|  |  |  | Change |  |  |
| Assets | 58,149 | 57,322 | +827 | 55,245 | +2,904 |
| Current | 20,950 | 19,409 | +1,541 | 15,144 | +5,806 |
| L C\&CE* | 6,317 | 5,445 | +872 | 4,092 | +2,225 |
| Non-current | 37,199 | 37,913 | (714) | 40,101 | $(2,902)$ |
| Liabilities | 27,532 | 26,506 | +1,026 | 21,893 | +5,639 |
| Current | 16,120 | 15,702 | +418 | 11,675 | +4,445 |
| Non-current | 11,412 | 10,804 | +608 | 10,218 | +1,194 |
| ※ Total debt | 5,840 | 6,355 | (515) | 2,973 | +2,867 |
| Equity | 30,617 | 30,817 | (200) | 33,352 | $(2,735)$ |
| Controlling | 25,526 | 25,818 | (292) | 30,405 | $(4,879)$ |
| Non-controlling | 5,091 | 4,999 | +92 | 2,947 | +2,144 |
| Debt/Equity (\%) | 90\% | 86\% | +4\%p | 66\% | +24\%p |

* C\&CE: Cash and cash equivalents + short-term financial instruments, etc.

|  | 3Q22 | 2Q22 | 2021 |
| :---: | :---: | :---: | :---: |
| Cash (Beginning of period) | 2,087 | 2,337 | 2,402 |
| Cash flows from operating activities | +1,467 | +81 | +1,196 |
| Net profit | +597 | +633 | +1,829 |
| Changes in operating assets and liabilities | +486 | (719) | $(1,414)$ |
| Others | +384 | +167 | +781 |
| Cash flows from investing activities | +114 | $(3,659)$ | (804) |
| Changes in tangible/intangible assets | (317) | (218) | (541) |
| Changes in equities | +239 | $(1,169)$ | +315 |
|  | +192 | $(2,272)$ | (578) |
| Cash flows from financing activities | (553) | +3,328 | (539) |
| Changes in borrowings | (600) | +2,195 | (182) |
| Others | +47 | +1,133 | (357) |
| Increase in cash | +1,028 | (250) | (147) |
| Cash (End of period) | 3,115 | 2,087 | 2,255 |


[^0]:    ※ Total sales include figures falling under Other Sales

